{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:34:48Z","timestamp":1788388488590,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.pcad.2025.08.004","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:49:20Z","timestamp":1755614960000},"page":"30-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis"],"prefix":"10.1016","volume":"93","author":[{"given":"Ellen","family":"Kronzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ledet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wells","family":"Askew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panithaya","family":"Chareonthaitawee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2025.08.004_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","article-title":"Cardiac sarcoidosis","volume":"68","author":"Birnie","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0010","first-page":"2663","article-title":"Cardiac manifestations of sarcoidosis: diagnosis and management","volume":"38","author":"Birnie","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2021.100936","article-title":"Cardiac sarcoidosis: a clinical overview","volume":"46","author":"Alba","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0020","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","article-title":"Diagnosis and Management of Cardiac Sarcoidosis: a scientific statement from the American Heart Association","volume":"149","author":"Cheng","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.004_bb0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/heartjnl-2019-316442","article-title":"Cardiac sarcoidosis: state-of-the-art review","volume":"107","author":"Kouranos","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2025.08.004_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","article-title":"Sarcoidosis","volume":"5","author":"Grunewald","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pcad.2025.08.004_bb0035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jdin.2022.07.006","article-title":"The prevalence and geographic distribution of sarcoidosis in the United States","volume":"9","author":"Nam","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.pcad.2025.08.004_bb0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14797\/mdcvj.1057","article-title":"Epidemiology, pathogenesis, and diagnosis of cardiac sarcoidosis","volume":"18","author":"Mathai","year":"2022","journal-title":"Method Debakey Cardiovasc J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MCP.0000000000000715","article-title":"Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors","volume":"26","author":"Arkema","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0050","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","article-title":"Management of cardiac sarcoidosis","volume":"45","author":"Sharma","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1378\/chest.10-0413","article-title":"Sarcoidosis in black women in the United States: data from the Black Women's Health Study","volume":"139","author":"Cozier","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2025.08.004_bb0060","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1378\/chest.14-1120","article-title":"Racial difference in sarcoidosis mortality in the United States","volume":"147","author":"Mirsaeidi","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2025.08.004_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0002-8703(99)70115-8","article-title":"Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies","volume":"138","author":"Uemura","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2012.10.021","article-title":"CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis","volume":"6","author":"Greulich","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0075","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","article-title":"Isolated cardiac sarcoidosis: a focused review of an under-recognized entity","volume":"25","author":"Okada","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1749-6632.1976.tb47058.x","article-title":"Clinicopathological study of fatal myocardial sarcoidosis","volume":"278","author":"Matsui","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pcad.2025.08.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101102","article-title":"30-year trends in the incidence, characteristics, and outcome of cardiac sarcoidosis in a nationwide cohort","volume":"3","author":"Poyhonen","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.pcad.2025.08.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.115.016258","article-title":"Letter by Al-Kindi and Oliveira regarding article \"cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study\"","volume":"132","author":"Al-Kindi","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2025.08.004_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028342","article-title":"Long-term outcomes of cardiac sarcoid: prognostic implications of isolated cardiac involvement and impact of diagnostic delays","volume":"12","author":"Sink","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2025.08.004_bb0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2967\/jnmt.124.268142","article-title":"Assessment of cardiac sarcoidosis with PET\/CT","volume":"53","author":"Liu","year":"2025","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.5858\/2009-0274-RA.1","article-title":"Cardiac sarcoidosis: a pathology-focused review","volume":"134","author":"Lagana","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0002-9343(77)90121-8","article-title":"Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11)","volume":"63","author":"Roberts","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.semnuclmed.2024.02.004","article-title":"Imaging of cardiac sarcoidosis: an update and future aspects","volume":"54","author":"Saric","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0120","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12350-017-0978-9","article-title":"Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"24","author":"Chareonthaitawee","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacep.2017.09.175","article-title":"Characterization of the electroanatomic substrate in cardiac sarcoidosis: correlation with imaging findings of scar and inflammation","volume":"4","author":"Muser","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0130","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.hrthm.2014.03.043","article-title":"HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis","volume":"11","author":"Birnie","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2025.08.004_bb0135","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jce.15191","article-title":"Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes","volume":"32","author":"Ezzeddine","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0140","article-title":"The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines","volume":"39","author":"Terasaki","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.pcad.2025.08.004_bb0145","first-page":"19","article-title":"Organ assessment instrument investigators, the WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.pcad.2025.08.004_bb0150","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1253\/circj.CJ-19-0508","article-title":"Japanese Circulation Society joint working, JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version","volume":"83","author":"Terasaki","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0155","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2021.04.022","article-title":"Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease","volume":"335","author":"Rosenbaum","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0160","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/0002-9149(89)90323-8","article-title":"Two-dimensional echocardiographic findings in systemic sarcoidosis","volume":"63","author":"Burstow","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12471-016-0847-1","article-title":"Post, pulmonary hypertension complicating pulmonary sarcoidosis","volume":"24","author":"Huitema","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.pcad.2025.08.004_bb0170","first-page":"949","article-title":"Advances in imaging for diagnosis and management of cardiac sarcoidosis","volume":"16","author":"Aggarwal","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0175","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1378\/chest.66.4.452","article-title":"Myocardial sarcoidosis presenting as acute mitral insufficiency","volume":"66","author":"Zoneraich","year":"1974","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2025.08.004_bb0180","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1093\/ejechocard\/jer184","article-title":"Response to steroid therapy in cardiac sarcoidosis: insights from myocardial strain","volume":"13","author":"Lo","year":"2012","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0185","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1007\/s00330-017-4824-x","article-title":"Delayed contrast-enhanced computed tomography in patients with known or suspected cardiac sarcoidosis: a feasibility study","volume":"27","author":"Aikawa","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0190","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1148\/radiol.213170","article-title":"Diagnostic accuracy of cardiac MRI versus FDG PET for cardiac sarcoidosis: a systematic review and meta-analysis","volume":"304","author":"Aitken","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.pcad.2025.08.004_bb0195","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamacardio.2022.2981","article-title":"Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis","volume":"7","author":"Athwal","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001728","article-title":"T2-weighted short-tau-inversion-recovery imaging reflects disease activity of cardiac sarcoidosis","volume":"8","author":"Tonegawa-Kuji","year":"2021","journal-title":"Open Heart"},{"key":"10.1016\/j.pcad.2025.08.004_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.121.013745","article-title":"Synthetic extracellular volume in cardiac magnetic resonance without blood sampling: a reliable tool to replace conventional extracellular volume","volume":"15","author":"Chen","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.pcad.2025.08.004_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.004417","article-title":"Comprehensive cardiovascular magnetic resonance assessment in patients with sarcoidosis and preserved left ventricular ejection fraction","volume":"9","author":"Greulich","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0220","first-page":"10193","article-title":"Artifacts in cardiac T1 and T2 mapping techniques - influence on reliable quantification","author":"Fenski","year":"2025","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.pcad.2025.08.004_bb0225","article-title":"Multiparametric mapping of cardiac magnetic resonance imaging in a tertiary referral centre: clinical experiences and challenges","volume":"55","author":"Kong","year":"2024","journal-title":"J Med Imag Radiat"},{"key":"10.1016\/j.pcad.2025.08.004_bb0230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005001","article-title":"Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and Meta-analysis","volume":"9","author":"Hulten","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0235","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jcmg.2022.10.018","article-title":"Prognostic value of late gadolinium enhancement detected on cardiac magnetic resonance in cardiac sarcoidosis","volume":"16","author":"Stevenson","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007488","article-title":"Assessment of the 2017 AHA\/ACC\/HRS guideline recommendations for implantable cardioverter-defibrillator implantation in cardiac sarcoidosis","volume":"12","author":"Kazmirczak","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0245","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCEP.113.000156","article-title":"Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias","volume":"7","author":"Crawford","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0250","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/jim-2016-000144","article-title":"Resolution of abnormal cardiac MRI T2 signal following immune suppression for cardiac sarcoidosis","volume":"64","author":"Crouser","year":"2016","journal-title":"J Invest Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0255","first-page":"930","article-title":"GLUT1 expression in tissue and (18)F-FDG uptake","volume":"45","author":"Avril","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0260","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12350-009-9179-5","article-title":"Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: a randomized controlled trial","volume":"17","author":"Cheng","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0265","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s12350-011-9422-8","article-title":"Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake","volume":"18","author":"Harisankar","year":"2011","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0270","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12350-019-01746-4","article-title":"Suppressing physiologic 18-fluorodeoxyglucose uptake in patients undergoing positron emission tomography for cardiac sarcoidosis: the effect of a structured patient preparation protocol","volume":"28","author":"Christopoulos","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0275","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2967\/jnumed.121.261981","article-title":"Comparison of the effect of three different dietary modifications on myocardial suppression in (18)F-FDG PET\/CT evaluation of patients for suspected cardiac sarcoidosis","volume":"62","author":"Ozutemiz","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0280","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12350-015-0226-0","volume":"23","author":"Manabe","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0285","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s12350-013-9798-8","article-title":"Complete somatostatin-induced insulin suppression combined with heparin loading does not significantly suppress myocardial 18F-FDG uptake in patients with suspected cardiac sarcoidosis","volume":"20","author":"Gormsen","year":"2013","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0290","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12350-016-0477-4","article-title":"Continuing evolution in preparation protocols for (18)FDG PET assessment of inflammatory or malignant myocardial disease","volume":"24","author":"Bois","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0295","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s12350-023-03209-3","article-title":"Utility of serum ketone levels for assessment of myocardial glucose suppression for (18)F-fluorodeoxyglucose PET in patients referred for evaluation of endocarditis","volume":"30","author":"Madamanchi","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0300","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00259-022-06062-7","article-title":"The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies","volume":"50","author":"Alfawara","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0305","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","article-title":"ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures","volume":"23","author":"Dilsizian","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0310","first-page":"436","article-title":"Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET\/CT?","volume":"46","author":"DiFilippo","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102088","article-title":"Quantification of metabolic activity in the evaluation of cardiac sarcoidosis","volume":"43","author":"Wiefels","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12350-020-02201-5","article-title":"Quantitative assessment of cardiac hypermetabolism and perfusion for diagnosis of cardiac sarcoidosis","volume":"29","author":"Miller","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0325","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.jcmg.2020.11.016","article-title":"Pre-treatment myocardial (18)FDG uptake predicts response to immunosuppression in patients with cardiac sarcoidosis","volume":"14","author":"Subramanian","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0330","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.jcmg.2021.01.023","article-title":"Quantitative FDG PET\/CT to guide treatment of cardiac sarcoidosis: a crucial step forward","volume":"14","author":"Chareonthaitawee","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0335","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jcmg.2019.01.011","article-title":"Repeatability and optimization of FDG positron emission tomography for evaluation of cardiac sarcoidosis","volume":"12","author":"Alvi","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0340","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12350-013-9828-6","article-title":"Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis","volume":"21","author":"Osborne","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0345","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","article-title":"Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis","volume":"21","author":"Ahmadian","year":"2014","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0350","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12350-016-0490-7","article-title":"The response of FDG uptake to immunosuppressive treatment on FDG PET\/CT imaging for cardiac sarcoidosis","volume":"24","author":"Ahmadian","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0355","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/ehjci\/jex146","volume":"18","year":"2017","journal-title":"Eur Heart J Cardiovasc Imag"},{"key":"10.1016\/j.pcad.2025.08.004_bb0360","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jcmg.2024.05.013","article-title":"Risk stratification in cardiac sarcoidosis with cardiac positron emission tomography: a systematic review and Meta-analysis","volume":"17","author":"Kafil","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0365","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.amjcard.2023.06.101","article-title":"An international survey of current clinical practice in the treatment of cardiac sarcoidosis","volume":"203","author":"De Bortoli","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0370","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","author":"Blankstein","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0375","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.ijcard.2016.11.142","article-title":"Serial FDG-PET scans help to identify steroid resistance in cardiac sarcoidosis","volume":"228","author":"Shelke","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0380","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s00259-018-4001-8","article-title":"Prognostic role of serial quantitative evaluation of (18)F-fluorodeoxyglucose uptake by PET\/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia","volume":"45","author":"Muser","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0385","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis","volume":"11","author":"Sperry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0390","article-title":"Utility of FDG PET and cardiac MRI in diagnosis and monitoring of immunosuppressive treatment in cardiac sarcoidosis","volume":"2","author":"Coulden","year":"2020","journal-title":"Radiol Cardiothorac Imag"},{"key":"10.1016\/j.pcad.2025.08.004_bb0395","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12350-019-01659-2","article-title":"FDG-PET in possible cardiac sarcoidosis: right ventricular uptake and high total cardiac metabolic activity predict cardiovascular events","volume":"28","author":"Tuominen","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101842","article-title":"Role of serial (18)F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis","volume":"35","author":"Okafor","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133273","article-title":"Long term prognosis in cardiac sarcoidosis under FDG-PET guided immunosuppressive therapy","volume":"432","author":"Imamura","year":"2025","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0410","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007030","article-title":"Complementary value of cardiac magnetic resonance imaging and positron emission tomography\/computed tomography in the assessment of cardiac sarcoidosis","volume":"11","author":"Vita","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0415","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/ehjci\/jex340","article-title":"Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis","volume":"19","author":"Wicks","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0420","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcmg.2023.11.010","article-title":"Hybrid magnetic resonance positron emission tomography is associated with cardiac-related outcomes in cardiac sarcoidosis","volume":"17","author":"Trivieri","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0425","first-page":"338","article-title":"State of the art in cardiac hybrid technology: PET\/MR","volume":"6","author":"Nappi","year":"2013","journal-title":"Curr Cardiovasc Imag Rep"},{"key":"10.1016\/j.pcad.2025.08.004_bb0430","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s12350-016-0616-y","article-title":"Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET\/MRI","volume":"25","author":"Nensa","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.pcad.2025.08.004_bb0435","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jcmg.2021.08.018","article-title":"Hybrid cardiac magnetic resonance\/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis","volume":"15","author":"Greulich","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0440","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2025.08.004_bb0445","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jcmg.2024.04.003","article-title":"FAPI PET imaging supports clinical decision making in academic cardiology practice: a pictorial imaging vignette","volume":"17","author":"Settelmeier","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2025.08.004_bb0450","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.hrthm.2024.08.013","article-title":"Detection of cardiac sarcoidosis with the artificial intelligence-enhanced electrocardiogram","volume":"22","author":"de Melo","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2025.08.004_bb0455","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000001193","article-title":"Artificial intelligence in cardiac sarcoidosis: ECG, Echo, CPET and MRI","author":"Umeojiako","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pcad.2025.08.004_bb0460","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3390\/diagnostics13142426","article-title":"Machine-learning-based diagnostics of cardiac sarcoidosis using multi-Chamber Wall motion analyses","volume":"13","author":"Eckstein","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.pcad.2025.08.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102195","article-title":"AI-enabled CT-guided end-to-end quantification of total cardiac activity in 18FDG cardiac PET\/CT for detection of cardiac sarcoidosis","volume":"48","author":"Miller","year":"2025","journal-title":"J Nucl Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202500115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003306202500115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:07:41Z","timestamp":1765775261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003306202500115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":93,"alternative-id":["S003306202500115X"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.004","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in fluorodeoxyglucose positron emission tomography (18FDG-PET) in the diagnosis and management of cardiac sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}